Pfizer on Thursday mentioned it’s going to transfer ahead with a once-daily model of its weight reduction capsule, danuglipron, after it noticed “encouraging” knowledge in an ongoing early-stage research.
The corporate evaluated a number of once-daily formulations of the drug and recognized one with “essentially the most favorable profile” when it comes to security and the way the physique reacts to the remedy.
Pfizer mentioned it plans to conduct extra early-stage trials within the second half of the yr to establish the perfect dose of the drug, with outcomes anticipated within the first quarter of subsequent yr, a spokesperson advised CNBC. The corporate mentioned these trials will “inform the registration enabling research,” that are utilized in functions for regulatory approval.
Danuglipron “has demonstrated good efficacy in a twice-daily formulation, and we consider a once-daily formulation has the potential to have a aggressive profile within the oral GLP-1 house,” outgoing Pfizer Chief Scientific Officer Dr. Mikael Dolsten mentioned in a launch. Notably, the corporate didn’t observe any liver issues of safety in sufferers who acquired once-daily formulations of the drug.
Pfizer is one in all a number of drugmakers racing to win a slice of the marketplace for a extremely fashionable class of weight reduction and diabetes medication known as GLP-1 agonists. Some analysts anticipate the business to be price roughly $100 billion by the tip of the last decade.
However Pfizer has to date struggled to interrupt into the market.
The pharmaceutical big in December discontinued a twice-daily model of danuglipron after sufferers had bother tolerating the drug in a mid-stage research. On the time, Pfizer mentioned early research knowledge on the once-daily model would “inform a path ahead.”
However traders have been pessimistic in regards to the firm’s potential within the GLP-1 house ever because it scrapped a distinct once-daily capsule in June 2023 because of elevated liver enzymes in sufferers who acquired the remedy. These had been amongst a string of setbacks Pfizer confronted final yr on high of the speedy decline of its Covid enterprise, which battered its inventory.
Nonetheless, Pfizer has different experimental weight problems medication in early phases of growth. The corporate has not disclosed how these remedies will work.
“Weight problems is a key therapeutic space for Pfizer, and the corporate has a sturdy pipeline of three scientific and several other pre-clinical candidates,” Dolsten mentioned within the launch.
Pfizer additionally believes GLP-1s are solely “scratching the floor of what we’ll see in weight problems,” CEO Albert Bourla mentioned throughout a convention in June.
Pfizer’s danuglipron is a GLP-1 that promotes weight reduction in the identical approach as Novo Nordisk’s injection Wegovy and diabetes remedy Ozempic. The medication mimic a single hormone produced within the intestine known as GLP-1, which indicators to the mind when an individual is full.
Injections from Novo Nordisk and Eli Lilly have soared in demand during the last yr regardless of their hefty worth tags and restricted insurance coverage protection.
The pair – together with Pfizer and different drugmakers – has been racing to develop oral variations which are extra handy for sufferers to take and simpler to fabricate, which might assist alleviate provide shortages within the U.S.
Pfizer has beforehand mentioned it might purchase or associate with a smaller weight problems drugmaker.
Bourla advised reporters at a convention in January that it was unlikely Pfizer would purchase an weight problems remedy in later-stage growth, particularly as the corporate focuses on chopping prices.
However he mentioned Pfizer was searching for potential licensing offers or earlier-stage weight reduction medication.
Pfizer’s replace on danuglipron comes days after the corporate mentioned it’s looking for a successor to Dolsten, who will step down after greater than 15 years on the drugmaker. Dolsten performed a vital position in creating Pfizer’s Covid vaccine.
